Results 1 to 10 of about 2,902,189 (362)

The contribution of smoking-attributable mortality to differences in mortality and life expectancy among US African-American and white adults, 2000-2019

Demographic Research, 2022
Background: The role of smoking in racial disparities in mortality and life expectancy in the United States has been examined previously, but up-to-date estimates are generally unavailable, even though smoking prevalence has declined in recent decades.
Brian L. Rostron, Cindy M. Chang, Brittny C. Davis Lynn, Chunfeng Ren, Esther Salazar, Bridget K. Ambrose   +5 more
doaj   +1 more source

Dimensional variability characterization of additively manufactured lattice coupons

3D Printing in Medicine, 2022
Background Additive manufacturing (AM), commonly called 3D Printing (3DP), for medical devices is growing in popularity due to the technology’s ability to create complex geometries and patient-matched products.
Kirstie Lane Snodderly, Magdalene Fogarasi, Yutika Badhe, Ankit Parikh, Daniel Porter, Albert Burchi, Laura Gilmour, Matthew Di Prima   +7 more
doaj   +1 more source

Ecological prevalence, genetic diversity and epidemiological aspects of Salmonella isolated from tomato agricultural regions of the Virginia Eastern Shore

Frontiers in Microbiology, 2015
Virginia is the third largest producer of fresh-market tomatoes in the United States. Tomatoes grown along the eastern shore of Virginia are implicated almost yearly in Salmonella illnesses.
Rebecca L. Bell, Jie eZheng, Erik eBurrows, Sarah eAllard, Charles Y. Wang, Christine E. Keys, David C. Melka, Errol eStrain, Yan eLuo, Marc William Allard, Steven eRideout, Eric Wayne Brown   +11 more
doaj   +1 more source

Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014–2018)

BMC Health Services Research, 2021
Background A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program for certain medications with serious safety concerns required by the U.S. Food and Drug Administration (FDA) of manufacturers to implement to help ensure the benefits of
Linda Huynh, Gita A. Toyserkani, Elaine H. Morrato   +2 more
doaj   +1 more source

Interventions and compliance

Journal of Agriculture, Food Systems, and Community Development, 2020
Preventing the spread of infectious disease relies heavily upon the development and implementation of public health interventions. The requisite debate over the effectiveness of these interventions is accom­panied by discussions about which, if any ...
Girvin Liggans, Devin Dutilly, Komita Carrington-Liggans, Mary Cartagena, Charles Idjagboro, Laurie Williams, Glenda Lewis, Mia Russell, Veronica Moore, Robert Sudler   +9 more
doaj   +1 more source

The FDA’s Diverse and Dynamic Activities in the Social and Behavioral Sciences: Advancing and Supporting Health Equity

Journal of Primary Care & Community Health, 2021
The U.S. encompasses a heterogenous mix of people and health disparities exist for various subpopulations, such as minorities, women, people with limited English proficiency, those with low socioeconomic status, and other underserved groups.
Christine Lee, Melanie J. McLean, Caroline J. Huang, Anh Nguyen Zarndt, Kathryn J. Aikin, Paula Rausch, Barbara R. Cohen, Janine Delahanty, Danielle M. Sholly, Wendy I. Slavit, Ewa D. Carlton   +10 more
doaj   +1 more source

BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways

OncoImmunology, 2019
Immune checkpoint inhibitors (ICIs) such as the anti-PD-1 antibody Nivolumab, achieve remarkable clinical efficacy in patients with late stage cancers. However, only a small subset of patients benefit from this therapy.
Peng Yue, Taylor Harper, Silvia M. Bacot, Monica Chowdhury, Shiowjen Lee, Adovi Akue, Mark A. Kukuruga, Tao Wang, Gerald M. Feldman   +8 more
doaj   +1 more source

Informing selection of drugs for COVID-19 treatment through adverse events analysis

Scientific Reports, 2021
Coronavirus disease 2019 (COVID-19) is an ongoing pandemic and there is an urgent need for safe and effective drugs for COVID-19 treatment. Since developing a new drug is time consuming, many approved or investigational drugs have been repurposed for ...
Wenjing Guo, Bohu Pan, Sugunadevi Sakkiah, Zuowei Ji, Gokhan Yavas, Yanhui Lu, Takashi E. Komatsu, Madhu Lal-Nag, Weida Tong, Tucker A. Patterson, Huixiao Hong   +10 more
doaj   +1 more source

Evaluating the potential of gold, silver, and silica nanoparticles to saturate mononuclear phagocytic system tissues under repeat dosing conditions

Particle and Fibre Toxicology, 2017
Background As nanoparticles (NPs) become more prevalent in the pharmaceutical industry, questions have arisen from both industry and regulatory stakeholders about the long term effects of these materials. This study was designed to evaluate whether gold (
James L. Weaver, Grainne A. Tobin, Taylor Ingle, Simona Bancos, David Stevens, Rodney Rouse, Kristina E. Howard, David Goodwin, Alan Knapton, Xiaohong Li, Katherine Shea, Sharron Stewart, Lin Xu, Peter L. Goering, Qin Zhang, Paul C. Howard, Jessie Collins, Saeed Khan, Kidon Sung, Katherine M. Tyner   +19 more
doaj   +1 more source

Decoding kinase-adverse event associations for small molecule kinase inhibitors

Nature Communications, 2022
Small molecule kinase inhibitors (SMKIs) are being approved at a fast pace under expedited programs for anticancer treatment. Here, the authors employ a machine-learning model to examine the relationships between kinase targets and adverse events in the ...
Xiajing Gong, Meng Hu, Jinzhong Liu, Geoffrey Kim, James Xu, Amy McKee, Todd Palmby, R. Angelo de Claro, Liang Zhao   +8 more
doaj   +1 more source